Depending on whom you ask, Alfred Engelberg could be a hero or a villain in the story of American pharmaceuticals. The patent lawyer helped write legislation that led to a dramatic increase in the number of generic drugs on the market. He also contributed to a patent system that gives pharmaceutical companies monopolies on their most lucrative drugs, blocking generic competition and keeping prices...
Alfred Engelberg's story is a microcosm of the broader tensions in pharmaceutical policy. On one hand, his work on the Hatch-Waxman Act was intended to foster competition and lower drug prices. On the other, his later exploitation of the system's loopholes underscores how legal frameworks can be gamed to maintain monopolies. The narrative invites reflection on the balance between innovation incentives and consumer access to affordable medications.
The article does not exhibit clear manipulation ...